Table 4.
Overall response based on prior immunotherapy history in patients who received QL1706 at 5 mg/kg every 3 weeks (RP2D)
| All patients (n = 468) | Primary tumor type | |||||||
|---|---|---|---|---|---|---|---|---|
| NSCLC (n = 121) | NPC (n = 110) | CC (n = 55) | ||||||
| Immunotherapy-naive patients (n = 312) | Immunotherapy-treated patients (n = 156) | Immunotherapy-naive patients (n = 66) | Immunotherapy-treated patients (n = 55) | Immunotherapy-naive patients (n = 62) | Immunotherapy-treated patients (n = 48) | Immunotherapy-naive patients (n = 53) | Immunotherapy-treated patients (n = 2) | |
| CR, n (%) | 1 (0.3) | 0 | 0 | 0 | 0 | 0 | 1 (1.9) | 0 |
| PR, n (%) | 71 (22.8) | 7 (4.5) | 16 (24.2) | 1 (1.8) | 24 (38.7) | 3 (6.3) | 14 (26.4) | 0 |
| SD, n (%) | 81 (26.0) | 48 (30.8) | 15 (20.7) | 22 (40.0) | 13 (21.0) | 14 (29.2) | 14 (26.4) | 0 |
| PD, n (%) | 133 (42.6) | 80 (51.3) | 32 (48.3) | 20 (36.4) | 24 (38.7) | 28 (58.3) | 16 (30.2) | 2 (100) |
| NE, n (%) | 2 (0.6) | 0 | 0 | 0 | 0 | 0 | 1 (1.9) | 0 |
| ND, n (%) | 24 (7.7) | 21 (13.5) | 3 (5.2) | 12 (21.8) | 1 (1.6) | 3 (6.3) | 7 (13.2) | 0 |
| Confirmed ORR, n (%, 95% CI) | 72 (23.1, 18.5–28.1) | 7 (4.5, 1.8–9.0) | 16 (24.2, 14.5–36.4) | 1 (1.8, 0.04–9.7) | 24 (38.7, 26.6–51.9) | 3 (6.3, 1.3–17.2) | 15 (28.3, 16.8–42.3) | 0 |
| DCR, n (%, 95% CI) | 153 (49.0, 43.3–54.7) | 55 (35.3, 27.8–43.3) | 31 (47.0, 34.6–60.0) | 23 (41.8, 28.7–55.9) | 37 (59.7, 46.5–71.9) | 17 (35.4, 22.2–50.5) | 29 (54.7, 40.4–68.4) | 0 |
| Number of DoR events (%) | 16 (22.2) | 4 (57.1) | 4 (25.0) | 1 (100) | 7 (29.2) | 2 (66.7) | 2 (13.3) | / |
| DoR, m (95% CI) | − (8.1, –) | 11.7 (4.2, 11.7) | − (3.5, –) | / | − (7.7, –) | 11.7 (5.9, 11.7) | − (–, –) | / |
NSCLC Non-small-cell lung cancer, NPC Nasopharyngeal carcinoma, CC Cervical cancer, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease, NE Not evaluated, ND Not determined, ORR Objective response rate, DCR Disease control rate, CI Confidence interval, DoR Duration of response